Skip to main content
. Author manuscript; available in PMC: 2014 Jan 24.
Published in final edited form as: J Immunol. 2010 Dec 3;186(1):312–322. doi: 10.4049/jimmunol.1001989

FIGURE 7.

FIGURE 7

Th1-type versus Th2-type immunoreactivity of spontaneous LAGE-1–specific CD4+ T cells in patients with melanoma and healthy donors. A and B, Representative dot plots from melanoma patients MP7, MP8, MP1, and healthy donors ND1, ND2, ND3 (A), and summary data for NY-ESO-1+/ LAGE-1+ melanoma patients (n = 16), NY-ESO-1−/LAGE-1− melanoma patients (n = 5), and healthy donors (n = 16) (B) showing the percentages or combined numbers of LAGE-1–specific IFN-γ and/or IL-5–producing CD4+ T cells per 105 CD4+ T cells in 6 h ICS assays performed after 10–12 d IVS with either peptide LAGE-197–114, peptide LAGE-1104–121, or peptide LAGE-1118–135 as described in Materials and Methods. In B, each symbol depicts the number of IFN-γ– and/or IL-5–producing CD4+ T cells per 105 CD4+ T cells in the presence of the relevant LAGE-1 peptide minus the numbers of cytokine producing CD4+ T cells in the presence of the irrelevant peptide HIVpol711–725. A positive response is defined as the number of LAGE-1–specific cytokine-producing cells per 105 CD4+ T cells greater than the mean + 3 SD of the cytokine-producing cell number obtained from all healthy donors and patients against the control peptide HIVpol711–725. The mean values of IFN-γ– and IL-5–producing CD4+ T cells in the presence of the irrelevant peptide HIVpol711–725 were 25 (SD, 10) and 22 (SD, 9), respectively.